Immunotherapy News and Research

Latest Immunotherapy News and Research

Damon Runyon holds fourth annual Accelerating Cancer Cures Research Symposium

Today, the Damon Runyon Cancer Research Foundation held the fourth annual Accelerating Cancer Cures Research Symposium. The yearly meeting is designed to encourage collaboration between cancer researchers in industry and their counterparts in academia in order to overcome many of the issues that currently impede progress against cancer.

3 Mar 2015

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel reported a net loss of $22.3 million, or $0.25 per share, compared to a net loss of $16.9 million, or $0.19 per share, in the fourth quarter of 2013.

3 Mar 2015

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that it has licensed a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen.

2 Mar 2015

TxCell invited to speak at largest US meeting for investors in emerging growth companies

In the presentation, Damian Marron will provide an overview of TxCell and its personalized T cell immunotherapy platform ASTrIA. Additional details will also be provided to institutional investors in one on one meetings at the conference.

27 Feb 2015

New test can predict survival chances of women with breast cancer

Scientists have developed a new test which can predict the survival chances of women with breast cancer by analysing images of 'hotspots' where there has been a fierce immune reaction to a tumour.

27 Feb 2015

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).

25 Feb 2015

MD Anderson researchers find way to predict patients who may respond to BRAF inhibitors

Powerful drugs known as BRAF-inhibitors have been crucial for melanoma patients, saving lives through their ability to turn off the BRAF protein's power to spur cancer cell growth.

24 Feb 2015

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors.

23 Feb 2015

MD Anderson awarded more than $22 million in research grants from CPRIT

The University of Texas MD Anderson Cancer Center has received more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas. Approximately half of the funds awarded for Individual Investigator Research Awards went to MD Anderson faculty as well as 40 percent of total IIRA awards that include those for children's and adolescent cancer and early detection and prevention.

21 Feb 2015

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Cancer vaccines are designed to turn the body's own immune system specifically against tumor cells. Particularly promising are vaccines that are directed against so-called neoantigens: These are proteins that have undergone a genetic mutation in tumor cells and, therefore, differ from their counterparts in healthy cells.

20 Feb 2015

Study results pave way for new clinical trial for glioblastoma patients

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research.

19 Feb 2015

New NIH grant to support development of rapid method for diagnosing mucormycosis

Speed is essential in treating deadly mucormycosis fungal infections, but a quick diagnosis is difficult because no routine blood test exists.

19 Feb 2015

NYU Langone, Technion collaborate to advance cancer research

In a groundbreaking step forward to advance global collaboration in the fight against cancer, two of the world's preeminent academic and research institutions -- NYU Langone Medical Center and the Technion-Israel Institute of Technology -- formally announced a $9 million gift from philanthropists Laura and Isaac Perlmutter that will fund two major, joint research endeavors with potentially far-reaching impact in advancing cancer research.

19 Feb 2015

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Amgen announced today that the Cellular, Tissue and Gene Therapies Advisory Committee and the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration will jointly review the Company's Biologics License Application (BLA) for talimogene laherparepvec.

11 Feb 2015

Discovery improves understanding of factors that trigger allergic asthma

When the mucosal surfaces in the lungs of healthy people come into contact with allergenic substances, so-called regulatory T cells also known as Treg cells, are activated. These are capable of actively preventing the development of allergies.

9 Feb 2015

Crown Bioscience, NRCMM partner to develop new immune-oncology experimental cancer models

Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.

6 Feb 2015

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapies addressing high-unmet medical needs, today announced the closing of its previously disclosed exclusive global license agreement for the therapeutic use of Samcyprone with Hapten Pharmaceuticals, LLC.

5 Feb 2015

Scientists investigate how T cells in colorectal tumors actively fight cancer

In recent years, a standard follow-up to colorectal cancer surgery has been to analyze the tumor tissue for the presence of immune cells. Finding high quantities of cytotoxic T cells, or "killer cells", means that there is a good chance that the disease will take a favorable course and that the risk of metastasis is comparatively low.

5 Feb 2015

Research findings demonstrate new approach to transform behavior of tumor cells

Inserting a specific strain of bacteria into the microenvironment of aggressive ovarian cancer transforms the behavior of tumor cells from suppression to immunostimulation, researchers at Norris Cotton Cancer Center and the Geisel School of Medicine at Dartmouth have found.

5 Feb 2015

BioMed Realty Trust expands footprint in Seattle's core innovation district of South Lake Union

BioMed Realty Trust, Inc. today announced that it is under contract to acquire the 307 Westlake Avenue North building in the heart of the burgeoning South Lake Union life science market of Seattle, Washington for approximately $90 million.

4 Feb 2015

Immunotherapy News and Research

Latest Immunotherapy News and Research

Damon Runyon holds fourth annual Accelerating Cancer Cures Research Symposium

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

TxCell invited to speak at largest US meeting for investors in emerging growth companies

New test can predict survival chances of women with breast cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

MD Anderson researchers find way to predict patients who may respond to BRAF inhibitors

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

MD Anderson awarded more than $22 million in research grants from CPRIT

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Study results pave way for new clinical trial for glioblastoma patients

New NIH grant to support development of rapid method for diagnosing mucormycosis

NYU Langone, Technion collaborate to advance cancer research

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Discovery improves understanding of factors that trigger allergic asthma

Crown Bioscience, NRCMM partner to develop new immune-oncology experimental cancer models

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

Scientists investigate how T cells in colorectal tumors actively fight cancer

Research findings demonstrate new approach to transform behavior of tumor cells

BioMed Realty Trust expands footprint in Seattle's core innovation district of South Lake Union

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in